Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro

Background: The role of oncolytic viruses in cancer treatment is increasingly studied. The first oncolytic virus (Rigvir®, ECHO-7) was registered in Latvia over a decade ago. In a recent retrospective study Rigvir® decreased mortality 4.39-6.57-fold in stage IB-IIC melanoma patients. The aims of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tilgase, Andra, Patetko, Liene, Blāķe, Ilze, Ramata‑Stunda, Anna, Borodušķis, Mārtiņš, Alberts, Pēteris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868171/
https://www.ncbi.nlm.nih.gov/pubmed/29581783
http://dx.doi.org/10.7150/jca.23242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868171/
https://www.ncbi.nlm.nih.gov/pubmed/29581783
http://dx.doi.org/10.7150/jca.23242

Ejemplares similares